Compugen

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Compugen reports Q1 loss, showcases promising cancer immunotherapy approach

Compugen's Q1 2023 performance reflects a strategic focus on capital efficiency and milestone achievement.
Their innovative triple combination approach in cancer immunotherapy shows promise, with encouraging clinical benefits observed.
While managing R&D expenses and translating clinical benefits into marketable products are challenges, opportunities exist in disciplined cash deployment and exploration of biomarkers.
Overall, Compugen's financial discipline, promising clinical data, and strategic focus position them well for future growth in the oncology space.

Compugen (CGEN) reports positive ASCO results and solid financial standing

Compugen (CGEN) showcases promising results in cancer immunotherapy combinations, maintaining a strong financial position despite increased R&D expenses. The company's differentiated approach and focus on milestone achievement through 2024 position it well for future growth, although challenges in enrollment delays and managing expenses persist.

Compugen reports Q3 progress with promising clinical data and partnerships

Compugen's Q3 2023 performance reflects progress in clinical trials and financial stability with a cash balance of $57.5 million.
Strengths lie in innovative drug discovery approaches, successful clinical outcomes, and strategic partnerships.
Challenges include competitive enrollment landscape, cost management, and market acceptance of novel treatments.
Opportunities exist in upcoming data reporting, novel drug targets, and collaborations for future growth and success.

Compugen reports robust earnings and strategic partnerships drive growth

Compugen's Q4 2023 performance reflects strong financial results and notable achievements in clinical advancements and partnerships.
The company's financial stability, strategic focus, and robust pipeline position them well for future growth and innovation.
While facing challenges in clinical trial outcomes and partnership strategies, Compugen has opportunities to drive further growth through data insights and collaborations.

Compugen reports solid Q1 performance, poised for growth in 2024

Compugen's Q1 2024 performance reflects financial stability, operational efficiency, and progress in advancing key drug candidates towards clinical trials, underpinned by a robust AI discovery platform and strategic partnerships.
While challenges like ongoing R&D investments and achieving profitability persist, opportunities in milestone achievements, data readouts, and strategic collaborations position Compugen for future growth and value creation.
Navigating the biopharmaceutical landscape with innovation, financial discipline, and strategic foresight, Compugen stands poised to capitalize on market opportunities, drive pipeline progression, and enhance shareholder value.

Compugen reports Q2 revenue of $6.7M, highlights innovative drug strategies

Compugen's Q2 2024 performance reflects steady revenue generation and prudent financial management. The company's strengths in innovative drug development and strategic collaborations present promising growth opportunities. Addressing challenges in clinical evidence and cash burn will be crucial for sustained success.

Compugen reports solid Q3 earnings, advances promising ovarian cancer therapies

Compugen's strong financial position, promising clinical data on multiple therapies, and strategic focus on ovarian cancer treatment advancements position the company for potential growth. Challenges lie in maintaining treatment efficacy and navigating regulatory discussions for future developments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

COM701 in combination with nivolumab demonstrated encouraging 12% ORR in 3L+ MSS-CRC patients with liver metastases, compared to 0% ORR historically for other immunotherapies in a U.S. patient population Translational data showed potent immune activation in the tumor microenvironment (TME) in patients responding to treatment, atypical of immunotherapy in cold tumors like MSS-CRC Further clinical evaluation of COM701 + anti-PD-1 in combination with COM902 planned in MSS-CRC patients Management will discuss the preliminary data to be presented at SITC as part of the Q3 earnings call on Monday, November 14, 2022, at 8:30 am ET HOLON, Israel , Nov. 7, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today publication of an abstract on preliminary data showing anti-tumor activity and potent immune modulation with the combination of COM701 and nivolumab in metastatic MSS-CRC patients.

Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients

HOLON, Israel , Nov. 2, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on October 31, 2022, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement").

Compugen Announces Receipt of Nasdaq Delisting Notice

The stock's rise came after the company announced when third-quarter earnings will be presented.

Why Shares of Compugen Jumped 9.27% on Tuesday

HOLON, Israel , Oct. 31, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022, before the U.S. financial markets open.

Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022

Clinical data from COM701/nivolumab ± BMS-986207 combination studies in patients with platinum resistant ovarian cancer Clinical data from COM701±nivolumab study in patients with metastatic NSCLC who received prior immune checkpoints HOLON, Israel , Oct. 26, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that it will present new clinical data from its COM701/nivolumab with or without BMS-986207 combination studies in patients with platinum resistant ovarian cancer and data from COM701 with or without nivolumab study in patients with metastatic NSCLC as poster presentations at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) congress taking place between December 7-9, 2022, in Geneva, Switzerland.

Compugen to Present New Clinical Data at ESMO-IO

Clinical data from dual combination COM701/nivolumab MSS-CRC cohort expansion study Research data on differentiation of PVRIG from other immune checkpoints HOLON, Israel , Oct. 6, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that it will present new clinical data from its dual combination COM701/nivolumab MSS-CRC cohort expansion study and research data on the differentiation of PVRIG from other immune checkpoints in two oral presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 10-12 November 2022, Boston, MA.

Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022

HOLON, Israel , Sept. 22, 2022 /PRNewswire/ -- Compugen Ltd.

Compugen Letter to Shareholders

HOLON, Israel , Sept. 12, 2022 /PRNewswire/ -- Compugen Ltd.

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

YaronTurpaz, Ph.D., SVP and Senior Advisor, Computational Discovery, Compugen to participate in a panel discussion on leveraging artificial intelligence and machine learning to advance discovery and accelerate drug development.

Compugen to Participate in Upcoming Fierce Biotech Summit

Iridium Communications

Nano Dimension

Signify Health

Tesla

It was another down week for Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ). Shares of the ETF are finishing in the red today, marking the second straight week of declines.

5 Top Stocks Cathie Wood Sold This Week

HOLON, Israel , Aug. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Japan Patent Office has granted Compugen a new composition of matter and use patent covering its potentially first-in-class anti-PVRIG, COM701 and backup anti-PVRIG antibodies.

Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan

HOLON, Israel , Aug. 8, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the European Patent Office has granted Compugen a new patent covering anti-PVRIG antibodies for use in cancer treatment.

Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio

Compugen Ltd. (NASDAQ:CGEN ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Yvonne Naughton - Head of IR and Corporate Communications Anat Cohen-Dayag - President & CEO Ari Krashin - Chief Financial & Operating Officer Henry Adewoye - Chief Medical Officer Eran Ophir - Vice President Research & Drug Discovery Conference Call Participants Bonnie Quach - Stifel Mark Breidenbach - Oppenheimer Tony Butler - Roth Capital Daina Graybosch - SVB Leerink Reni Benjamin - JMP Securities Operator Ladies and gentlemen, thank you for joining us today.

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q2 2022 Results - Earnings Call Transcript

Prioritized two indications, MSS-CRC and NSCLC, utilizing fully owned assets, COM701 and COM902 Focus on MSS-CRC and NSCLC expected to provide highest probability of success and support future path to registration Focused development plan results in strategic decision to wind down Phase 1 cohort expansion studies resulting in the conclusion of collaboration with Bristol Myers Squibb Most advanced preclinical program with first-in-class potential entering pre-IND enabling studies Extended cash runway expected to last through the end of 2024 HOLON, Israel , Aug. 4, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, provided a corporate update and announced financial results for the second quarter ended June 30, 2022.

Compugen Reports Second Quarter 2022 Results

HOLON, Israel , July 21, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its second quarter financial results on Thursday, August 4, 2022, before the U.S. financial markets open.

Compugen to Release Second Quarter Results on Thursday, August 4, 2022

HOLON, ISRAEL , June 27, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that members of its management team will present at the following industry conferences in Europe: Event: 10th Antibody Industrial Symposium, Montpellier, France Date: Tuesday June 28, 2022 Presenter: Pierre Ferré, Ph.D.

Compugen to Present at Upcoming Industry Conferences

HOLON, Israel , June 1, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the following investor conferences: Event: Jefferies Healthcare Conference, New York City Date: Wednesday June 8, 2022 Fireside Chat Time:  1:30PM ET A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com.

Compugen to Present at Upcoming Investor Conferences

Triple blockade of PVRIG/TIGIT/PD-1 may be required to optimize clinical responses COM701, a unique check point inhibitor, with potential to recruit additional T cells to the TME COM902 has the potential to be a best-in-class anti-TIGIT antibody On track to deliver clinical data from the cohort expansion study of COM701/nivolumab in MSS CRC in Q4 2022 Enrollment continues in the Phase 1 clinical studies for COM701 and COM902 Cash balance of $107 million affirms focus on capital efficiency with bold execution on Compugen's DNAM-1 axis hypothesis HOLON, Israel , May 16, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today financial results for the first quarter ended March 31, 2022 and provided a corporate update on key events since the start of 2022.

Compugen Reports First Quarter 2022 Results

HOLON, Israel , May 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Mr.

Compugen Announces CFO Departure

HOLON, Israel , May 2, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its first quarter 2022 financial results on Monday, May 16, 2022, before the U.S. financial markets open.

Compugen to Release First Quarter 2022 on Monday, May 16, 2022

Archer Aviation

Atai Life Sciences BV

Cerus

Ginkgo Bioworks Holdings

Joby Aviation

Invitae

Quantum-Si

Zymergen

Are these Cathie Wood penny stocks a buy right now? The post 10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

HOLON, Israel, March 21, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen," the "Company"), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will give a presentation today on exploring the immune-tumor microenvironment (TME) using high resolution single-cell spatial transcriptomics at the Keystone Symposium: Cancer Immunotherapy: Decoding the Cancer Immunity Interactome, March 20-24 at Whistler, British Columbia, Canada.

Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment

HOLON, Israel , March 14, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give an oral presentation on exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics at the Keystone Symposium on Cancer Immunotherapy to take place on March 20-24, 2022, in British Columbia, Canada.

Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keystone Symposium

HOLON, Israel, March 9, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the Oppenheimer 32nd Annual Global Healthcare Conference (virtual), on Wednesday, March 16, 2022 at 11:20 am ET.

Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference

HOLON, Israel, March 9, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN),("Compugen," the "Company"), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the presentation of new research suggesting that targeting PVRIG and TIGIT holds promise for treating multiple myeloma.

News for Compugen Stock (CGEN)